Dapansutrile

DB16130InvestigationalSmall molecule

Dapansutrile is under investigation in clinical trial NCT01768975 (Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee).

Mechanism: Dapansutrile specifically inhibits the NLRP3 inflammasome and subsequent activation of IL-1β. It is currently being investigated against gout flares, joint pain and COVID-19.
Curator reviewed · 1 reference
Formula / weight: C₄H₇NO₂S · 133.17 g/mol (avg)
Code names: OLT-1177

Resolves to

Compound

UNII2Z03364G96CAS54863-37-5ChEMBLCHEMBL3989943

Structure

InChIKeyLQFRYKBDZNPJSW-UHFFFAOYSA-NSMILESCS(=O)(=O)CCC#N

Targets

Q96P20NLRP3

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dapansutrile, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account